Prolonged elimination half-life of phenol after dermal exposure. 1998

Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
Rambam Medical Center, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. ipic@rambam.health.gov.il

BACKGROUND Phenol is a general protoplastic poison which has been in use in medicine and industry for decades. It is readily absorbed through the skin causing both local and systemic toxicity. METHODS A 47-year-old male had 90% phenol spilled over his left foot and shoe (3% of body surface area). After a 4 1/2-hour exposure, manifestations included confusion, vertigo, faintness, hypotension, ventricular premature beats, atrial fibrillation, dark-green urine, and tense swelling, blue-black discoloration, hypalgesia, and hypoesthesia of the affected area. Treatment consisted of irrigation with copious amounts of water, incisions, and supportive measures. RESULTS Peak serum phenol was 21.6 micrograms/mL, considered in the fatal range. Peak urine phenol plus urine-conjugated phenol was 13,416 mg/g creatinine, indicating a major absorption. Elimination half-life was 13.86 hours, considerably longer than previously reported. CONCLUSIONS Prolonged skin contact with concentrated phenol in an occlusive environment may result in a major absorption and a long elimination half-life even if the area involved is small. Prolonged elimination may be explained by extensive tissue distribution or by "slow-release reservoir" properties of the skin. Such exposure may be associated with severe systemic and local toxicities. Immediate removal from exposure and aggressive decontamination of the skin are essential to reduce these risks.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012869 Skin Absorption Uptake of substances through the SKIN. Absorption, Skin,Intracutaneous Absorption,Intradermal Absorption,Percutaneous Absorption,Transcutaneous Absorption,Transdermal Absorption,Absorption, Intracutaneous,Absorption, Intradermal,Absorption, Percutaneous,Absorption, Transcutaneous,Absorption, Transdermal,Absorptions, Intracutaneous,Absorptions, Intradermal,Absorptions, Percutaneous,Absorptions, Skin,Absorptions, Transcutaneous,Absorptions, Transdermal,Intracutaneous Absorptions,Intradermal Absorptions,Percutaneous Absorptions,Skin Absorptions,Transcutaneous Absorptions,Transdermal Absorptions
D016273 Occupational Exposure The exposure to potentially harmful chemical, physical, or biological agents that occurs as a result of one's occupation. Exposure, Occupational,Exposures, Occupational,Occupational Exposures
D019800 Phenol An antiseptic and disinfectant aromatic alcohol. Carbol,Carbolic Acid,Hydroxybenzene,Phenol, Sodium Salt,Phenolate Sodium,Sodium Phenolate,Phenolate, Sodium

Related Publications

Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
April 1986, British journal of clinical pharmacology,
Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
July 1978, The Journal of antimicrobial chemotherapy,
Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
January 1996, Duodecim; laaketieteellinen aikakauskirja,
Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
June 1979, Southern medical journal,
Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
March 1990, The Journal of infection,
Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
January 1998, Soins; la revue de reference infirmiere,
Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
February 1987, Clinical and experimental immunology,
Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
January 1980, Clinical pharmacokinetics,
Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
March 1987, Pharmacology & toxicology,
Y Bentur, and O Shoshani, and A Tabak, and A Bin-Nun, and Y Ramon, and Y Ulman, and Y Berger, and T Nachlieli, and Y J Peled
June 2012, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!